

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

Mail Stop 3030

October 3, 2017

<u>Via E-mail</u> Mary Duseau President and Chief Executive Officer Roka BioScience, Inc. 20 Independence Boulevard Warren, NJ 07059

> Re: Roka BioScience, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 29, 2017 File No. 001-36538

Dear Ms. Duseau:

We have completed our limited review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Russell Mancuso

Russell Mancuso Branch Chief Office of Electronics and Machinery

cc: Steven Skolnick, Esq.